Sipuleucel-T
Provenge (sipuleucel-T) is a personalized cellular immunotherapy designed to treat metastatic castration-resistant prostate cancer that has spread and is no longer responding to hormone therapy. The treatment uses the patient's own immune cells, which are collected, sent to a laboratory where they are activated against prostate cancer proteins, and then reinfused back into the patient to help the immune system recognize and attack cancer cells.
Provenge is an autologous cellular immunotherapy for metastatic castration-resistant prostate cancer that uses the patient's own activated immune cells to target and fight cancer.
Key facts at a glance
- RxNorm
- 978086
- Generic
- Provenge
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Provenge is indicated for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). It is used when the cancer has spread beyond the prostate and is no longer responding to hormone-deprivation therapy.
Provenge is an autologous immunotherapy, meaning it is made from the patient's own immune cells. White blood cells are collected via leukapheresis, sent to a manufacturing facility where dendritic cells are activated using a recombinant antigen (PAP-GM-CSF fusion protein), and then reinfused into the patient to stimulate an immune response against prostate cancer cells.
Provenge is not a first-line treatment and is typically used when cancer has progressed after hormone therapy. Treatment consists of three infusions given approximately every two weeks. Common side effects may include chills, fever, fatigue, headache, joint ache, and nausea related to the infusion. As the treatment uses individual patient cells, the manufacturing and infusion schedule requires careful coordination between the treating physician and the specialty pharmacy.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 9, 2026. · Read our editorial policy